8-K filing — Perspective Therapeutics, Inc. (CATX)
Filed: 2026-10-08 AccNo: 0001193125-26-417384 Size: 224 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors
SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for